Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia
Highlights • Some biological factors were associated with achievement of early molecular response. • Some factors for early molecular response achievement can be modifiable. • Continuing the optimal dose intensity until 6 months is important for better outcomes.
Gespeichert in:
| Veröffentlicht in: | Leukemia research 2015-04, Vol.39 (4), p.411-418 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 418 |
|---|---|
| container_issue | 4 |
| container_start_page | 411 |
| container_title | Leukemia research |
| container_volume | 39 |
| creator | Lee, Sung-Eun Choi, Soo Young Oh, Yun Jeong Kim, Soo-Hyun Song, Hye-Young Yoo, Hea-Lyun Lee, Mi-Young Chae, Moon-Jung Kang, Ki-Hoon Hwang, Hee-Jeong Jang, Eun-Jung Kim, Dong-Wook |
| description | Highlights • Some biological factors were associated with achievement of early molecular response. • Some factors for early molecular response achievement can be modifiable. • Continuing the optimal dose intensity until 6 months is important for better outcomes. |
| doi_str_mv | 10.1016/j.leukres.2015.01.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1666295667</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0145212615000284</els_id><sourcerecordid>1666295667</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-5dc220c4a44e355664ed076cda267f410512fd97694e2afba38e2a43823afea23</originalsourceid><addsrcrecordid>eNqFUsFu1DAQtRCIbgufAPKRSxbbsZ3kAkIFSqVKHApny-uMtd46drCTlfIXfHId7ZYDl0ojjWy9eTPz5iH0jpItJVR-PGw9zA8J8pYRKraElqAv0Ia2TV2JthYv0YZQLipGmbxAlzkfCCGio91rdMGEbIlgfIP-fnV5csFMeEzQOzO5I2CrzRRTxi5YP0MwgGPA2uwdHGGAMOFoMejkFzxED2b2OuEyyRhDBrxbsE0xTN4FwG7Qhd3tChU2-_LtDB73usCeXsMCProer9vA4PQb9Mpqn-HtOV-h39-__br-Ud39vLm9_nJXGc7IVIneMEYM15xDLYSUHHrSSNNrJhvLKRGU2b5rZMeBabvTdVsyr1tWawua1Vfow4l3TPHPDHlSg8sGvNcB4pwVlVKyrhA3BSpOUJNizgmsGlNZLC2KErUeQx3U-RhqPYYitAQtde_PLebdAP2_qif1C-DzCQBl0aODpLJxq969S2Am1Uf3bItP_zGYorsz2j_AAvkQ5xSKioqqzBRR96sjVkNQUczAWl4_Ao9ftj0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1666295667</pqid></control><display><type>article</type><title>Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Lee, Sung-Eun ; Choi, Soo Young ; Oh, Yun Jeong ; Kim, Soo-Hyun ; Song, Hye-Young ; Yoo, Hea-Lyun ; Lee, Mi-Young ; Chae, Moon-Jung ; Kang, Ki-Hoon ; Hwang, Hee-Jeong ; Jang, Eun-Jung ; Kim, Dong-Wook</creator><creatorcontrib>Lee, Sung-Eun ; Choi, Soo Young ; Oh, Yun Jeong ; Kim, Soo-Hyun ; Song, Hye-Young ; Yoo, Hea-Lyun ; Lee, Mi-Young ; Chae, Moon-Jung ; Kang, Ki-Hoon ; Hwang, Hee-Jeong ; Jang, Eun-Jung ; Kim, Dong-Wook</creatorcontrib><description>Highlights • Some biological factors were associated with achievement of early molecular response. • Some factors for early molecular response achievement can be modifiable. • Continuing the optimal dose intensity until 6 months is important for better outcomes.</description><identifier>ISSN: 0145-2126</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/j.leukres.2015.01.011</identifier><identifier>PMID: 25680524</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Benzamides - therapeutic use ; Biomarkers, Tumor - genetics ; Chronic myeloid leukemia ; Early molecular response ; Female ; Follow-Up Studies ; Fusion Proteins, bcr-abl - genetics ; Hematology, Oncology and Palliative Medicine ; Humans ; Imatinib ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Male ; Middle Aged ; Neoplasm Staging ; Piperazines - therapeutic use ; Prognosis ; Pyrimidines - therapeutic use ; Real-Time Polymerase Chain Reaction ; Reverse Transcriptase Polymerase Chain Reaction ; RNA, Messenger - genetics ; Survival Rate ; Time Factors ; Young Adult</subject><ispartof>Leukemia research, 2015-04, Vol.39 (4), p.411-418</ispartof><rights>2015</rights><rights>Copyright © 2015. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-5dc220c4a44e355664ed076cda267f410512fd97694e2afba38e2a43823afea23</citedby><cites>FETCH-LOGICAL-c420t-5dc220c4a44e355664ed076cda267f410512fd97694e2afba38e2a43823afea23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.leukres.2015.01.011$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25680524$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Sung-Eun</creatorcontrib><creatorcontrib>Choi, Soo Young</creatorcontrib><creatorcontrib>Oh, Yun Jeong</creatorcontrib><creatorcontrib>Kim, Soo-Hyun</creatorcontrib><creatorcontrib>Song, Hye-Young</creatorcontrib><creatorcontrib>Yoo, Hea-Lyun</creatorcontrib><creatorcontrib>Lee, Mi-Young</creatorcontrib><creatorcontrib>Chae, Moon-Jung</creatorcontrib><creatorcontrib>Kang, Ki-Hoon</creatorcontrib><creatorcontrib>Hwang, Hee-Jeong</creatorcontrib><creatorcontrib>Jang, Eun-Jung</creatorcontrib><creatorcontrib>Kim, Dong-Wook</creatorcontrib><title>Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>Highlights • Some biological factors were associated with achievement of early molecular response. • Some factors for early molecular response achievement can be modifiable. • Continuing the optimal dose intensity until 6 months is important for better outcomes.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides - therapeutic use</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Chronic myeloid leukemia</subject><subject>Early molecular response</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fusion Proteins, bcr-abl - genetics</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Imatinib</subject><subject>Imatinib Mesylate</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Piperazines - therapeutic use</subject><subject>Prognosis</subject><subject>Pyrimidines - therapeutic use</subject><subject>Real-Time Polymerase Chain Reaction</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>RNA, Messenger - genetics</subject><subject>Survival Rate</subject><subject>Time Factors</subject><subject>Young Adult</subject><issn>0145-2126</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsFu1DAQtRCIbgufAPKRSxbbsZ3kAkIFSqVKHApny-uMtd46drCTlfIXfHId7ZYDl0ojjWy9eTPz5iH0jpItJVR-PGw9zA8J8pYRKraElqAv0Ia2TV2JthYv0YZQLipGmbxAlzkfCCGio91rdMGEbIlgfIP-fnV5csFMeEzQOzO5I2CrzRRTxi5YP0MwgGPA2uwdHGGAMOFoMejkFzxED2b2OuEyyRhDBrxbsE0xTN4FwG7Qhd3tChU2-_LtDB73usCeXsMCProer9vA4PQb9Mpqn-HtOV-h39-__br-Ud39vLm9_nJXGc7IVIneMEYM15xDLYSUHHrSSNNrJhvLKRGU2b5rZMeBabvTdVsyr1tWawua1Vfow4l3TPHPDHlSg8sGvNcB4pwVlVKyrhA3BSpOUJNizgmsGlNZLC2KErUeQx3U-RhqPYYitAQtde_PLebdAP2_qif1C-DzCQBl0aODpLJxq969S2Am1Uf3bItP_zGYorsz2j_AAvkQ5xSKioqqzBRR96sjVkNQUczAWl4_Ao9ftj0</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Lee, Sung-Eun</creator><creator>Choi, Soo Young</creator><creator>Oh, Yun Jeong</creator><creator>Kim, Soo-Hyun</creator><creator>Song, Hye-Young</creator><creator>Yoo, Hea-Lyun</creator><creator>Lee, Mi-Young</creator><creator>Chae, Moon-Jung</creator><creator>Kang, Ki-Hoon</creator><creator>Hwang, Hee-Jeong</creator><creator>Jang, Eun-Jung</creator><creator>Kim, Dong-Wook</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia</title><author>Lee, Sung-Eun ; Choi, Soo Young ; Oh, Yun Jeong ; Kim, Soo-Hyun ; Song, Hye-Young ; Yoo, Hea-Lyun ; Lee, Mi-Young ; Chae, Moon-Jung ; Kang, Ki-Hoon ; Hwang, Hee-Jeong ; Jang, Eun-Jung ; Kim, Dong-Wook</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-5dc220c4a44e355664ed076cda267f410512fd97694e2afba38e2a43823afea23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides - therapeutic use</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Chronic myeloid leukemia</topic><topic>Early molecular response</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fusion Proteins, bcr-abl - genetics</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Imatinib</topic><topic>Imatinib Mesylate</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Piperazines - therapeutic use</topic><topic>Prognosis</topic><topic>Pyrimidines - therapeutic use</topic><topic>Real-Time Polymerase Chain Reaction</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>RNA, Messenger - genetics</topic><topic>Survival Rate</topic><topic>Time Factors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Sung-Eun</creatorcontrib><creatorcontrib>Choi, Soo Young</creatorcontrib><creatorcontrib>Oh, Yun Jeong</creatorcontrib><creatorcontrib>Kim, Soo-Hyun</creatorcontrib><creatorcontrib>Song, Hye-Young</creatorcontrib><creatorcontrib>Yoo, Hea-Lyun</creatorcontrib><creatorcontrib>Lee, Mi-Young</creatorcontrib><creatorcontrib>Chae, Moon-Jung</creatorcontrib><creatorcontrib>Kang, Ki-Hoon</creatorcontrib><creatorcontrib>Hwang, Hee-Jeong</creatorcontrib><creatorcontrib>Jang, Eun-Jung</creatorcontrib><creatorcontrib>Kim, Dong-Wook</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Sung-Eun</au><au>Choi, Soo Young</au><au>Oh, Yun Jeong</au><au>Kim, Soo-Hyun</au><au>Song, Hye-Young</au><au>Yoo, Hea-Lyun</au><au>Lee, Mi-Young</au><au>Chae, Moon-Jung</au><au>Kang, Ki-Hoon</au><au>Hwang, Hee-Jeong</au><au>Jang, Eun-Jung</au><au>Kim, Dong-Wook</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>39</volume><issue>4</issue><spage>411</spage><epage>418</epage><pages>411-418</pages><issn>0145-2126</issn><eissn>1873-5835</eissn><abstract>Highlights • Some biological factors were associated with achievement of early molecular response. • Some factors for early molecular response achievement can be modifiable. • Continuing the optimal dose intensity until 6 months is important for better outcomes.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>25680524</pmid><doi>10.1016/j.leukres.2015.01.011</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0145-2126 |
| ispartof | Leukemia research, 2015-04, Vol.39 (4), p.411-418 |
| issn | 0145-2126 1873-5835 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1666295667 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Adult Aged Antineoplastic Agents - therapeutic use Benzamides - therapeutic use Biomarkers, Tumor - genetics Chronic myeloid leukemia Early molecular response Female Follow-Up Studies Fusion Proteins, bcr-abl - genetics Hematology, Oncology and Palliative Medicine Humans Imatinib Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Male Middle Aged Neoplasm Staging Piperazines - therapeutic use Prognosis Pyrimidines - therapeutic use Real-Time Polymerase Chain Reaction Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger - genetics Survival Rate Time Factors Young Adult |
| title | Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T08%3A38%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distinct%20predictive%20factors%20influence%20on%20achievement%20of%20early%20molecular%20response%20by%20frontline%20imatinib%20in%20chronic%20phase%20chronic%20myeloid%20leukemia&rft.jtitle=Leukemia%20research&rft.au=Lee,%20Sung-Eun&rft.date=2015-04-01&rft.volume=39&rft.issue=4&rft.spage=411&rft.epage=418&rft.pages=411-418&rft.issn=0145-2126&rft.eissn=1873-5835&rft_id=info:doi/10.1016/j.leukres.2015.01.011&rft_dat=%3Cproquest_cross%3E1666295667%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1666295667&rft_id=info:pmid/25680524&rft_els_id=S0145212615000284&rfr_iscdi=true |